MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

NCT06531395 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-05-21

No results posted yet for this study

Summary

Primary objective of the study is to evaluate the effect of abiprubart on an established systemic disease activity measure for Sjögren's Disease.

Conditions

  • Sjögrens Disease

Interventions

DRUG

Abiprubart

humanized monoclonal antibody

DRUG

Placebo

sterile preservative-free solution

Sponsors & Collaborators

  • Kiniksa Pharmaceuticals, GmbH

    collaborator INDUSTRY

  • Kiniksa Pharmaceuticals International, plc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-17
Primary Completion
2025-03-06
Completion
2025-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06531395 on ClinicalTrials.gov